HPV vaccine ‘could substantially reduce’ cervical cancer incidence

November 25, 2011

Source: Cancer Research UK

Follow this link for fulltext

Date of publication: November 2011

Publication type: News item

In a nutshell: Research published in the Lancet Oncology says the human papillomavirus (HPV) vaccine Cervarix “offers excellent protection” against serious cell changes that lead to cervical cancer, particularly when given to young adolescent girls before they become sexually active.

Length of publication: Webpage


Two HPV tests better than one for cervical screening

October 17, 2011

Source: Cancer Research UK

Follow this link for fulltext

Date of publication: August 2011

Publication type: Press release

In a nutshell: A Swedish study showed that doing the Human papillomavirus (HPV) test twice with a short interval in between would reduce the number of women having unnecessary treatment. The study also suggested that home testing could increase the number of women screened.

Length of publication: Webpage


A new approach to cervical screening

August 8, 2011

Source: The Lancet Oncology

Follow this link for abstract

Date of publication: June 2011

Publication type: Journal article

In a nutshell: The present method of screening for cervical cancer – reading Pap smears for abnormal cells – has led to a decrease in incidence and mortality from cervical cancer. However, false-positive and false-negative readings happen regularly. The article discusses a new approach.

Length of publication: 2 pages

Some important notes: You will need to register on The Lancet website to access the full text of this article. Registration is free of charge.


HPV testing to be included in NHS cervical screening programme

February 14, 2011

Source: Cancer Research UK

Follow this link for fulltext

Date of publication: January 2011

Publication type: News item

In a nutshell: The inclusion of human papillomavirus (HPV) testing in the current NHS Cervical Screening Programme from April 2011 has been confirmed in the programme’s annual review, published on January 7th. The HPV test – which looks for the presence of certain high-risk strains of the human papillomavirus – will be offered to women with borderline or low-grade cervical abnormalities detected in the first round of cervical screening. Once HPV testing has been brought in, only those women with borderline changes who also test positive for HPV will be referred for a detailed colposcopy examination. This will reduce the number of women who undergo unnecessary procedures.

Length of publication: Webpage


Follow

Get every new post delivered to your Inbox.